Lilly leaps into new frontier of cancer drugs
For two years, Eli Lilly and Co. has been building a team of immuno-oncology researchers in New York City and has struck a series of deals with other drug companies.
For two years, Eli Lilly and Co. has been building a team of immuno-oncology researchers in New York City and has struck a series of deals with other drug companies.
A new analysis shows attempts by drugmakers to raise prices are being wiped out in negotiations with managers of drug insurance benefits like Express Scripts Holding Co. and CVS Health Corp.
A shortage of primary care physicians and emerging alternatives such as retail clinics and smartphone apps are changing the way patients access the U.S. health care system.
The market for health-insurance in the U.S. is already so highly concentrated that pending tie-ups among four of the country’s largest insurers risk hurting both consumers and doctors, the American Medical Association said.
On Oct. 1, the nation’s physicians and hospitals must start using a massive new coding system to describe your visit on insurance claims so they get paid.
The grant will enable researchers at IU's Indianapolis medical campus to develop and implement the IU Health Careers Opportunity Program.
CEO Bryan Mills has set a goal to make 75 percent of revenue—or $1.5 billion a year—be covered by value-based contracts—which means Community would be rewarded for keeping patients out of the hospital. A new venture is Mills’ strategy to get there.
Marian University expects the deans of both its medical and nursing schools to retire in the next two years. So, the small Catholic school is launching a search for replacements.
The experimental medicine, called romosozumab, showed better results than Eli Lilly and Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement Wednesday.
Daniel Evans Jr. plans to leave his post as president immediately and retire as CEO on May 1. The system’s chief operating officer, Dennis Murphy, will take over as president now and as CEO in the spring.
More paying customers helped Community Health Network pull in $47 million in second-quarter profits, a story being repeated at not-for-profit hospitals around the country as Obamacare has boosted the number of insured customers to unprecedented highs.
A recent study found the number of health insurers offering broad provider networks on the Obamacare exchange was higher than in all but 10 other states and suggests that so long as Hoosiers keep singing “Don’t Fence Me In,” they could keep paying more for health insurance.
Calibrium LLC and MB2 LLC, both based in Carmel, have agreed to be sold for undisclosed amounts. They were developing diabetes drugs discovered by the research team of Richard DiMarchi, a chemistry professor at Indiana University.
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
Although the $10 million Pike Township YMCA has no timetable for completion, officials have pledged to offer extensive services to veterans in conjunction with the Richard L. Roudebush VA Medical Center.
Profits at most county-owned hospitals have grown by 100 percent to 400 percent over the past four years via partnerships with nursing homes that have brought in hundreds of millions of dollars in extra federal money.
The IU Board of Trustees gave unanimous approval to the 45,000-square-foot addition to the school at IUPUI. It is expected to open in 2020.
Dr. Bill Tierney, who has led the Regenstrief medical informatics research operation for five years, will become chair of the department of population health at the Dell Medical School at the University of Texas at Austin.
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
Concerns about serious side effects, including fainting, complicate discussions about whether to cover Sprout Pharmaceuticals' Addyi.